Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 9/20 | 0.52 |
| ▸ | MMP8 | P22894 | 2/20 | 0.52 |
| ▸ | CTSC | P53634 | 2/20 | 0.47 |
| ▸ | FCER2 | P06734 | 2/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 10/20 | 0.43 |
| ▸ | MMP3 | P08254 | 6/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2184747 | 0.87 | MMP1 (0.51) | MMP1MMP8CTSCNAALAD2MMP2 | |
| SCHEMBL2196939 | 0.85 | PTPN1 (0.50) | MMP1MMP8CTSCNAALAD2 | |
| SCHEMBL31607204 | 0.84 | MME (0.55) | CTSCNAALAD2MMP2MMP7MME | |
| SCHEMBL31380447 | 0.83 | NAALAD2 (0.65) | MMP1MMP8CTSCNAALAD2MME | |
| SCHEMBL29488057 | 0.83 | NAALAD2 (0.65) | MMP1MMP8CTSCNAALAD2MME | |
| SCHEMBL30692733 | 0.83 | NAALAD2 (0.65) | MMP1MMP8CTSCNAALAD2MME | |
| SCHEMBL28438258 | 0.83 | CHRND (0.48) | — | |
| SCHEMBL29574387 | 0.82 | MME (0.56) | CTSCNAALAD2MMP2MMP7MME | |
| SCHEMBL27450014 | 0.82 | MME (0.56) | CTSCNAALAD2MMP2MMP7MME | |
| SCHEMBL27450013 | 0.82 | MME (0.56) | CTSCNAALAD2MMP2MMP7MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | MMP1 1154/4885MMP8 2359/4885CTSC 383/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | MMP1 653/4885MMP8 1239/4885CTSC 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.